Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urinary Bladder Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING